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Abstract
Nucleolin (NCL) is a major nucleolar phosphoprotein that has pleiotropic effects on cell proliferation and is elevated in a
variety of tumors. NCL is highly phosphorylated at the N-terminus by two major kinases: interphase casein kinase 2 (CK2)
and mitotic cyclin-dependent kinase 1 (CDK1). Earlier we demonstrated that a NCL-mutant that is partly defective in
undergoing phosphorylation by CK2 inhibits chromosomal replication through its interactions with Replication Protein A,
mimicking the cellular response to DNA damage. We further delineated that the N-terminus of NCL associates with Hdm2,
the most common E3 ubiquitin ligase of p53. We reported that NCL antagonizes Hdm2 to stabilize p53 and stimulates p53
transcriptional activity. Although NCL-phosphorylation by CK2 and ribosomal DNA transcription are closely coordinated
during interphase, the role of NCL phosphorylation in regulating cell proliferation remains unexplored. We have therefore
engineered unique human cells that specifically induce expression of NCL-wild type (WT) or a phosphorylation-deficient
NCL-mutant, 6/S*A where all the six CK2 consensus serine sites residing in the N-terminus NCL were mutated to alanine.
Here we show that this NCL-mutant is defective in undergoing phosphorylation by CK2. We also demonstrate that NCL-
phosphorylation by CK2 is required through the S-phase progression in cell cycle and hence proliferation. Induced
expression of NCL with mutated CK2 phosphorylation sites stabilizes p53, results in higher expression of Bcl2 (B-cell
lymphoma 2) homology 3 (BH3)-only apoptotic markers and causes a dominant-negative effect on cell viability. Our unique
cellular system thus provides the first evidential support to delineate phospho-specific functions of NCL on cell proliferation.
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Introduction
Nucleolin (NCL or C23), a ubiquitously expressed phospho-
protein constitutes almost 10% of total nucleolar proteins. NCL
protein has multiple sub-cellular locations that are directly
implicated in its pleotropic physiological functions. In the
nucleolus, it is directly involved in cellular processes e.g. chromatin
remodeling [1], transcriptional regulation [2], ribosome biogenesis
[3] and telomerase activity [4]. In the nucleoplasm, it interacts
with several proteins and is involved in regulation of the cellular
response to stress [5–10]. NCL constantly shuttles between the
nucleus and cytoplasm where it is involved in many non nucleolar
functions e.g. centrosome duplication [11] as well as post-
transcriptional and translational regulation of various mRNAs
[12–14] including p53 [15]. On the cell surface NCL serves as a
receptor, binds to several ligands to either mediate tumorigenesis
or to relay anti-carcinogenic effects [16].
Differential NCL localization is due to changes in its isoelectric
point and/or post-translational modifications that include: glyco-
sylation [17], ADP-ribosylation [18], acetylation [19] and most
importantly phosphorylation [20–23]. NCL is a substrate for a
variety of kinases and NCL phosphorylation has been implicated
in its diverse physiological functions. In exponentially dividing
cells, casein kinase 2 (CK2) phosphorylates NCL at the consensus
serine sites (typically ‘SEDE’ motifs) residing in its N-terminus
[23–25]. Increases in CK2 activity and heightened phosphoryla-
tion of NCL by CK2 are positively correlated with active rDNA
transcription, rRNA synthesis, cell growth and proliferation
[20,26,27]. During mitosis, cyclin-dependent kinase 1 (CDK1)
phosphorylates threonine within ‘TPKK’ motifs that are also
located in the N-terminal domain of NCL [21,28]. In sum, NCL
phosphorylation regulates cell cycle and sub-cellular localization
that is linked to nucleolar reorganization during mitosis [29,30].
Besides the phosphorylation sites, the N-terminal domain of NCL
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also harbors acidic stretches (that interact with histones) and basic
regions (that interact with DNA), leading to its role in chromatin
decondensation [31]. It can be envisioned that sequential CK2
and CDK1 phosphorylation could modulate NCL function in
controlling cell proliferation (growth and division) between
interphase and the mitotic phase of the cell cycle.
RNA binding properties of NCL are conferred by its four RNA
binding domains that are adjacent to the N-terminus. NCL has
been described as a stress responsive RNA binding protein [6].
NCL translocation from nucleoli to nucleoplasm in response to
different stresses [5,32] has been linked to its role in inhibiting
DNA replication [7,33,34], controlling DNA repair [35,36] and
gene transcription [37–39]. Together, these data indicate that
NCL mobilization releases a part of the NCL pool to modulate
DNA and RNA metabolism following stress.
NCL also has distinct mechanisms in p53 regulation. We
previously demonstrated that in cells with hyperproliferative
signals but no obvious DNA damage, NCL stabilizes p53 protein
[8]. We demonstrated that the N-terminus and central RNA
binding domains of NCL associate strongly with Hdm2 to inhibit
p53 degradation in vitro [9]. However, upon DNA damage a part
of the NCL pool can bind p53 mRNA and repress p53 translation
[15] while stabilizing Bcl2 (B-cell lymphoma 2) mRNA, a
downstream target of the p53 signaling in the cytoplasm [13].
On the other hand, mobilization of NCL upon DNA damage
alters NCL interactions with the ribosomal subunit RPL26 (60S
ribosomal protein L26) and the p53 antagonist Hdm2 leading to
an increase in p53 mRNA translation and protein stability
[5,9,40]. Thus, NCL protein regulates the p53 signaling pathway
at multiple levels, providing a fine-tuning on cell survival during
cellular response to stress. Nonetheless, the role of NCL
phosphorylation by CK2 on cell survival and proliferation
functions remains largely unknown.
We have engineered unique system using human NARF6 cells
[41]. The NARF6 cells which were originally derived from human
osteosarcoma U2OS (ATCC) cells, express wt-p53 as well as
support the IPTG (isopropyl b-D-1-thiogalactopyranoside) -
regulated expression of the p14ARF (Alternate Reading Frame),
an upstream regulator of p53 during oncogenic stimulation [41].
We have genetically modified NARF6 cells through retroviral
infection such that to further support induced expression of either
NCL wild type (WT) or a CK2 phosphorylation-deficient mutant
(6/S*A; containing six alanine substitutions at the consensus serine
sites) by a Tet-off promoter system. Hereafter we refer to these
modified cells as NARF6 NCL clones or inducible NCL (WT or
6/S*A) cells. In this study we demonstrate the importance of these
six consensus CK2 sites on NCL and demonstrate that CK2
phosphorylation-deficient NCL mutant triggers p53 checkpoint
activation and inhibits cell proliferation by activating pro-
apoptotic markers.
Results
Nucleolin mutations at the CK2 phosphorylation sites
significantly reduces its phosphorylation
In order to reveal phosphorylation specific NCL functions, we
created a NCL-6/S*A construct where the six consensus CK2 sites
were mutated from serine to alanine (Figure 1A). To examine the
effect of the NCL-6/S*A mutation on phosphorylation, His-
tagged NCL-WT or the 6/S*A mutant, expressed in U2OS cells
and were purified by affinity chromatography. After SDS-PAGE,
proteins were stained with Pro-Q Diamond for quantifying
phosphorylated Ser, Thr and Tyr residues [42]. Subsequent
staining of the same gel with SYPRO Ruby for total protein
content [43] revealed that the NCL-6/S*A mutant was only 16%
phosphorylated as compared to WT, demonstrating that the
mutation of the six CK2 sites greatly reduces NCL phosphory-
lation (Figure 1B, 1C, *p,0.05). Anti-NCL is shown in a parallel
gel for the Western blot detection. Preliminary studies by our
laboratory indicate that the nucleolin phosphorylation by CDK1
however, remains unchanged between NCL-WT and 6/S*A (K.
Ng and A. Saxena, unpublished data). These data thus strongly
suggest that CK2 is the major kinase that phosphorylates NCL
during interphase, confirming an earlier report [21].
Nucleolin phospho-variants demonstrate distinct
sub-nuclear localization and mobility upon genotoxic
stress
Earlier we demonstrated that partial dephosphorylation at CK2
sites leads significant fraction of NCL to localize in the nucleoplasm
[7,33,34]. We therefore examined sub-nuclear localization of NCL-
6/S*A. Both WT and the 6/S*A mutant primarily localized to the
nucleoli (punctate staining, Figure 1D) upon transient transfection
or stable inducible expression (refer to later sections for details
regarding inducible cells). Additionally, NCL-6/S*A is also readily
localized in the nucleoplasm as compared to WT (Figure 1D). To
quantitate the sub-nuclear distribution of NCL localization, we
examined a total of ,80-100 nuclei with differential levels of NCL
expression (low, medium and high) in both WT and 6/S*A
expressing cells. Integrated morphometric analyses performed in
cells with moderate level of NCL expression (n = 30 for each WT
and 6/S*A) reveal that a significantly larger fraction of nuclear 6/
S*A (60.064.0%, at **p,0.005) was localized in the nucleoplasm as
compared to that of WT (which is only at 35.568.5% of the total)
(Figure S1). Occasionally we observe larger nucleoli, in cells
expressing either NCL-6/S*A or WT. Such differences can be
attributed to asynchrony of cell population and nucleolar fusion
during S and G2 phase of the cell cycle that has been reported in the
literature [44].
Because sub-nuclear translocation of NCL has been implicated
in its role in regulating DNA replication, the cellular response to
stress, and p53 activation, we examined NCL localization before
and after genotoxic stress in inducible NCL cells. Both NCL
variants (WT and 6/S*A) translocate completely to nucleoplasm
upon treatment with the topoisomerase I inhibitor camptothecin
(CPT, 2 mM for 2 h). Exposure to UV (50 J/m2) had a reduced
effects on each variant, with WT and 6/S*A both showing a
combination of nucleolar and nucleoplasmic localization
(Figure 1E). These data indicate that the NCL-6/S*A mutation
mimics the effect of stress by causing partial NCL translocation
from the nucleolus to the nucleoplasm even under non-stress
conditions.
These studies used a static approach to measure NCL
localization. The greater nucleoplasmic localization of the 6/S*A
mutant suggests a more mobile NCL. Therefore we investigated
the effect of the mutation on NCL dynamics to measure its intra-
nuclear mobility by fluorescence recovery after photobleaching
(FRAP). FRAP experiments revealed that when nucleoli express-
ing GFP-tagged NCL were photobleached, ,4 s faster recovery of
fluorescence was observed with NCL phospho-mutant (*p,0.05,
Figure S2). At least 10 data sets were analyzed by FRAP as
described [45]. Although genotoxic stress caused greater mobility
of both WT and the 6/S*A mutant, the mutant consistently
showed higher mobility compared to WT under these conditions
(*p,0.05, Figure S2).
To investigate the mechanism of nucleolin regulation by CK2, we
performed in vivo phosphorylation assay in the presence of CK2
inhibitor DRB (5, 6-Dichloro-1-b-D-ribofuranosylbenzimidazole)
Nucleolin CK2-Sites in Proliferation
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and analyzed NCL phosphorylation as well as sub-nuclear
localization. As indicated in Figure S3, we observed a significant
decrease in 32P labeled NCL in the presence of CK2 inhibitor DRB
when equivalent amount of NCL immunoprecipitates were
assessed. Intriguingly, although use of the CK2 inhibitor DRB
can be expected to have more pleiotropic effects, DRB treatment of
cells also resulted in greater NCL mobilization (Figure S3).
These data strongly suggest that NCL hypophosphorylation at
the consensus CK2 sites mobilizes NCL from the nucleoli in a
manner similar to that earlier reported during cellular stresses
(Figure 1E, [5,7,9]).
Inducible expression of nucleolin phospho-variants
activate the p53 checkpoint
We created retroviral constructs that express both the Tet
activator and a 3xFlag-tagged NCL-WT or NCL-6/S*A from a
single DNA molecule. We stably transfected NARF6 cells with
these constructs; the NARF6 cells also express p14ARF from an
IPTG-inducible promoter [41]. Stable clones were isolated that
showed tetracycline (or doxycycline) regulated expression of NCL.
Multiple clones were selected: Control cells (Ctrl, with no
exogenous NCL expression, vector alone), WT (that express
3xFlag-NCL WT) and 6/S*A (expressing phosphorylation-defi-
cient NCL mutant). Tests of a representative clone demonstrates
expression of 3xFlag-NCL only upon doxycycline removal
(Figure 2A) that almost completely shuts off when doxycycline is
added back in the growth medium. In this study we present data
from inducible NCL cells when exogenous NCL expression was
induced by removal of doxycycline for a range of 1–28 days.
Earlier we reported that exogenous NCL expression stabilizes
p53 levels and regulates its transcriptional activity [8], therefore,
we examined the effects of NCL-WT and 6/S*A expression on
p53 protein levels. When cells were induced continuously for WT
and 6/S*A expression (from 7–28 days grown without doxycy-
cline), both variants resulted in an increase in p53 protein levels
although greater increase was observed with NCL-6/S*A expres-
sion (Figure 2B). Interestingly, NCL-WT expression showed
dynamic expression (with periodic variation) of p53 levels when
cells grown at different days without doxycycline. On the other
hand, continuous induction of NCL-6/S*A expression resulted in
more persistent (sustained) p53 protein levels. Corresponding to
the p53 levels, increases in p21 protein-the downstream target of
p53- were also observed (Figure 2B). The scatter plot representing
the p53 and p21 protein levels during the 7 to 28 days of induced
Figure 1. Characterization of phosphorylation-deficient NCL-mutant. (A) Targeting the consensus CK2 sites in NCL: The modular structure
of NCL protein is shown, indicating the positions of principal domains. The six consensus CK2 sites (all serine) that were mutated to alanine in the 6/
S*A construct are denoted by asterisks (*). An enlarged schematic of the N-terminal domain is also shown. (B) Nucleolin (NCL)-6/S*A is
hypophosphorylated: Purified His-tagged NCL proteins were subjected to SDS-PAGE and fluorescently stained and visualized for phospho-specific
Pro-Q Diamond and SYPRO-Ruby protein (for total NCL) dyes. Anti-NCL is a representative Western blot. NCL-6/S*A relative phosphorylation is
represented as the ratio of its Pro-Q signal to that of NCL-WT, after normalizing for the total NCL signal using NIH Image J software. NCL-6/S*A was
only phosphorylated at 16% the level of WT, due to its mutated CK2 sites. (C) Values in the bar graph are the mean 6S.E.M. from three experiments
from ProQ and SYPRO-Ruby staining of NCL-variants. *Statistically different from NCL-WT phosphorylation, p,0.05. (D) Sub-nuclear localization of
NCL-WT and -6/S*A: Sub-nuclear localization of transiently transfected GFP-NCL (green) and stable inducible 3xFlag-NCL (red) in U2OS cells as
detected by anti-Flag antibodies. Under normal (unstressed) conditions, both WT and the 6/S*A mutant are primarily localized to the nucleoli
(punctate staining). A significantly larger fraction of nuclear 6/S*A (60.064.0%, **p,0.005) was localized in the nucleoplasm as compared to that of
WT (which is only at 35.568.5% of the total). Nucleoplasmic staining (diffused within nucleus) is shown with white arrows. For quantitation refer to
Figure S1. (E) Sub-nuclear localization of 3xFlag-NCL (red) upon DNA damaging conditions: NCL (WT and 6/S*A) translocate completely to
nucleoplasm upon treatment with topoisomerase I inhibition by camptothecin (CPT, 2 mM for 2 h) while post-UV (50 J m22) at 25 min, both WT and
mutant are significantly located in nucleoli as well as nucleoplasm. Scale bar represents 10 mm.
doi:10.1371/journal.pone.0109858.g001
Nucleolin CK2-Sites in Proliferation
PLOS ONE | www.plosone.org 3 October 2014 | Volume 9 | Issue 10 | e109858
expression of WT or 6/S*A expression as compared to the Ctrl
cells strongly indicated that both p53 and p21 levels were higher in
6/S*A expressing cells (Figure 2C). However, these mutant cells
show fluctuating levels of p21 even with consistent p53 levels
(Figure 2B, 2C). Control cells on the other hand had minimal
effect on p53 or p21 levels during their growth without
doxycycline.
We further characterized our NCL-expressing clones and
confirmed that these cells have retained inducible p14ARF
expression and subsequent p53 stabilization, as described earlier
[41]. As depicted with two representative clones C1 and C2, both
NCL-WT and p14ARF expression lead to an increase in p53
protein levels and a corresponding increase in p21 levels (Figure
S4). Note that a smaller increase of p53 levels is observed with
expression of NCL alone (Figure S4, lane 1 vs. lane 3). As
expected, p53 half-life is drastically increased (beyond 2 h) upon
robust p14ARF expression (Figure S5). Endogenous NCL half-life
remains overall unaltered although a transient increase (of NCL)
upon p14ARF expression is consistently observed (Figure S5; lanes
3, 4 vs. lane 2).
Next we tested the possibility of using these NCL expressing cell
lines as an NCL-replacement tool. We utilized the fact that our
3xFlag-NCL constructs do not contain the 39UTR (untranslated
region) of the endogenous NCL mRNA and selectively downreg-
ulated the endogenous NCL by siRNA. Following two subsequent
siRNA transfection and post 36 h of second siRNA treatment, we
observe up to 70% reduction of endogenous NCL protein (anti-
NCL blot, lower band). The induced NCL expression (i.e. the
Flag-NCL by anti-NCL blot, upper band)) remained unchanged
(Figure S6). In contrast siRNA that targets coding region of NCL
gene downregulates both endogenous as well as induced NCL
(data not shown, [8]). Although NCL silencing normally causes
adverse effects on ribosome biogenesis [46], these novel cell lines
allow us to replace the endogenous NCL with minimal toxic side
effects when required. It should be noted that the induced NCL
levels (at 10 d) are only 40% (for WT) or less (for mutant) that of
endogenous NCL, we have therefore restricted endogenous NCL
silencing to 60–70% to avoid any artifacts due to cell toxicity. The
p53 protein levels were reduced with NCL-WT expression but
remained unchanged or slightly increased with NCL-6/S*A
expression, when endogenous NCL protein is reduced to 30–
40%. Although we still observe some higher p21 levels upon
endogenous NCL silencing as previously reported (Figure S6, [8]).
In summary, inducible NCL cells support the ability to express
both p14ARF (in the presence of 1 mM IPTG, usually for 16–
22 h) as well as full-length NCL phospho-variants (by removing
doxycycline from growth medium for at least 24–48 h) in a very
controlled manner. These are the first human cell lines that allow
us to turn on or off the expression of two nucleolar proteins,
p14ARF and NCL as well as can serve as an important NCL-
replacement tool.
Expression of nucleolin phosphorylation-deficient
mutant increases p53 protein half-life
We focused on clones expressing different phospho-variants of
NCL (WT or 6/S*A) to delineate the functional role/s of NCL
phosphorylation by CK2 in regulating the p53 signaling pathway.
Figure 2. NARF6-NCL clones with inducible NCL (WT or 6/S*A) expression. (A) Western blot of a representative clone that expresses 3xFlag-
NCL under Tet-off promoter in NARF6 cells (derived from U2OS). (B) Western blot analyses for cells grown without Dx for the indicated period
showing inducible NCL-expression (WT or 6/S*A). Both WT and 6/S*A led to a net increase in p53 protein levels and corresponding p21 protein levels
-the downstream target of p53. (C) Plots of p53 and p21 protein levels shown in 2B. The quantification was done by NIH Image J software. Values
were first corrected for the b-actin levels and then compared to Ctrl (no exogenous NCL, no Dx day 7) cells. The graph is representative of at least
three independent experiments.
doi:10.1371/journal.pone.0109858.g002
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First, we determined the p53 protein half-life upon expression of
NCL phospho-variants by inhibiting protein synthesis by cyclo-
heximide. The p53 protein half-life was clearly increased with
NCL-6/S*A expression as compared to WT as indicated by a
representative Western blot (Figure 3A). The graph is a represen-
tative of three independent experiments, each performed in
duplicate (Figure 3B). We further evaluated p53-stability for
shorter time period following cycloheximide blocking. As indicated
in Figure S7 (upper panel) the p53 half-life is lower in cells
expressing WT (,30–40’) as compared to mutant (,1 h), while
control cells have normal half-life of ,15–20’. Assuming the
decrease in p53 protein levels is a pseudo-first order kinetic
process, the data presented in Figure 3B were also plotted on a log
scale to indicate indeed a higher p53 protein half-life in cells with
mutant-NCL expression (Figure S7, lower panel). Interestingly, we
also observed lower steady state levels of NCL-6/S*A which had a
reduced half-life (,2 h) as compared to WT (.6 h; Figure 3C).
The shorter half-life of NCL-6/S*A indicates that CK2 phos-
phorylation might regulate NCL protein stability as previously
suggested by others [47,48]. The observed fluctuations in the
expression pattern for 6/S*A, in part is due to differential stability
of nucleolar vs. nucleoplasmic levels of the protein [49].
Nucleolin mutant, defective in CK2 phosphorylation,
causes dominant-negative effect on cell proliferation in a
p53-dependent manner
To understand the physiological consequences in terms of
cellular fate upon the stabilized p53 protein levels, we examined
cell cycle progression and cell proliferation upon induced NCL-
WT and 6/S*A expression. Measurement of DNA content by
propidium iodide staining and subsequent profiling of the cell
cycle distribution revealed a significant decrease in the fraction of
cells in S-phase upon NCL-6/S*A expression (Figure 4A, **p
value #0.005). We also employed a more sensitive method to
determine to S-phase population, using a Click-iT EdU flow
cytometry assay to directly measure DNA synthesis. This assay
incorporates EdU (5-ethynyl-29-deoxyuridine), a thymidine analog
into DNA during an active DNA synthesis. As indicated in
Figure 4B, a representative of three independent experiments,
EdU positive cells were reduced from 47% (in WT) to 34% in 6/
S*A expressing cells.
The decreased proportion of cells in S-phase strongly suggest
that cells with continuous expression of NCL-6/S*A delay the cell
cycle, failing to progress through the S-phase. Indeed the MTS cell
proliferation assays demonstrated that NCL-6/S*A was inhibitory
to cell proliferation as compared with WT expressing or Ctrl cells
(Figure 4C).
To determine if the NCL-6/S*A mediated inhibition of cell
proliferation is p53-dependent, we used HCT116 p53-wt and null
cells [50]. As depicted in figure 4D, there was no significant
difference in proliferation rate with expression of NCL (WT or 6/
S*A) in p53-null background although lesser viability is evident
with 6/S*A. In the presence of p53-wt however, NCL-6/S*A
expression showed a significantly lower rate of cell proliferation as
compared to NCL-WT (Figure 4D). These data decisively
demonstrate that NCL phosphorylation-deficient mutant inhibits
cell proliferation in a p53-dependent manner. Intriguingly, the
inhibitory effect by NCL-6/S*A occurs in the presence of
endogenous NCL-WT. Thus, expression of phosphorylation-
deficient NCL mutant exerts dominant-negative effect on cell
proliferation.
All the three cell lines (Ctrl, expressing either inducible NCL-
WT or NCL-6/S*A) showed a comparable standard curves
showing linear 490 nm absorbance pattern to the number of living
cells (Figure S8, upper panel). As anticipated, all cells, in the
absence of induced NCL expression (i.e. when grown in presence
of doxycycline) had similar proliferation pattern (Figure S8, lower
panel).
Nucleolin (WT and 6/S*A) associate with endogenous-
NCL
We observe a dominant-negative effect on cell proliferation by
NCL-6/S*A. Earlier it was shown that NCL oligomerizes through
its RNA binding domain [40]. This leads to our hypothesis that
NCL-6/S*A binds to NCL-WT and negates WT functions. To
test our hypothesis, we performed co-immunoprecipitation assays
to precipitate Flag-tagged inducible NCL by M2-beads and
analyzed the bound fraction for endogenous NCL. Indeed
endogenous NCL was precipitated along with both Flag-tagged
NCL-WT and 6/S*A (Figure 5). These data demonstrate that
NCL-6/S*A can antagonize NCL-WT through protein-protein
interactions.
Lack of nucleolin phosphorylation by CK2 activates
expression of apoptotic markers downstream in the p53
pathway
To further elucidate NCL-6/S*A mediated inhibition of cell
proliferation, we analyzed markers in apoptotic pathway to obtain
information about the observed cellular fate. Since continuous
NCL expression causes activation of the p53 checkpoint
(Figure 2B), we examined cells with shorter (1 d, 4 d, 7 d) and
longer (25 d) NCL induction times to obtain a functional
understanding of this activation. As depicted in Figure 6A, we
observe increases in p53 levels with both WT and 6/S*A
expression as early as 24 h of NCL induction. We also saw that
p53 levels were fluctuating even at early time points of NCL-WT
induction (e.g. 1 d, 4 d) as compared to 6/S*A expression
(Figure 6A, compare lanes 5,6 vs. 9,10). As mentioned earlier,
p21 levels were mostly comparable to corresponding p53 levels.
Induced expression of NCL-6/S*A resulted in an increased level
Bcl-2 homology 3 (BH3)-only apoptotic marker proteins, BID
(BH3 interacting-domain death agonist), BIM and PUMA (p53
upregulated modulator of apoptosis) as compared to the Ctrl or
NCL-WT expressing cells (Figure 6A). Interestingly, these apo-
ptotic markers are also expressed as early as post 24 h of inducible
NCL mutant expression. The scatter plot presented in Figure 6B
clearly indicates that NCL-6/S*A expression causes higher levels
of BH3 only proteins, especially BID and PUMA, suggesting a role
for regulation of apoptosis in these cells.
We observed a similar increase in p53, BID and PUMA with
NCL mutant expression for longer induction periods (10–24 d,
Figure S9). A cumulative scatter plot for all the combined data
(with as little as 24 h to as long as 28 days of induced NCL
expression) clearly reveals increased levels of p53, BID and PUMA
with NCL-6/S*A expression as compared to WT or Ctrl cells
(Figure S10). The increases in p21 protein levels were not
significantly different over the tested induction period between
WT and 6/S*A.
The BH3-only proteins have been strongly implicated in
triggering Bax/Bak mediated apoptosis either directly or indirectly
by targeting the pro-survival proteins [51,52]. BID and PUMA are
transcriptional targets of p53, however, PUMA is essential for p53-
independent apoptotic pathways as well. BIM on the other hand is
not a direct p53 target but is required during DNA damage
induced cell death [53–55]. Although an initial increase in BIM
levels were observed in 6/S*A expressing cells especially at early
times in NCL induction (Figure 6, for 1 d, 4 d), BIM levels were
Nucleolin CK2-Sites in Proliferation
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Figure 3. Half-life analyses of p53 and NCL (WT and 6/S*A) proteins. Inducible NCL-cells grown without Dx for 17d to express either NCL-WT
or NCL-6/S*A. Ctrl represents control cells without exogenous NCL expression. Cells were then treated with cycloheximide (CHX, 40 mg/ml) for
indicated times. (A) Lysates were prepared and analyzed by Western blotting for p53, FLAG (for NCL expression) and the b-actin loading control. The
relative band intensities for NCL and p53 proteins were quantified following normalization with b-actin and are indicated below each blot. (B) Plot of
p53-expression levels following CHX treatment corrected for the b-actin levels. The graph is representative of three independent experiments done in
duplicates. Half-life of p53 is ,60 min for NCL-6/S*A, ,30–40 min for NCL-WT and ,15–20 min for Ctrl (vector) expressing cells. (C) NCL-6/S*A
expression levels are relatively low as compared to NCL-WT under steady state conditions. Half-life of NCL-6/S*A is significantly lower ,2 h as
against.6 h for NCL-WT suggesting CK2 phosphorylation might regulate NCL protein stability.
doi:10.1371/journal.pone.0109858.g003
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not significantly different among the Ctrl, WT and 6/S*A cells, at
later time points. However, there is a possibility that lack of NCL
phosphorylation by CK2 triggers BIM expression early on in
response to cellular stress that described with sub-nuclear
mobilization earlier. Together, limiting NCL phosphorylation by
CK2 can initiate apoptosis through both p53-dependent and
independent mechanisms.
Discussion
In the current study we have generated new cellular tools that
express CK2-specific full-length NCL phosphorylation variants
upon a Tet-off inducible promoter system. Using this approach,
we make the novel observation that NCL phosphorylation by CK2
at the six consensus sites is required for cell survival and cell
proliferation. Loss of phosphorylation at these CK2 sites results in
increased p53 levels activating the signaling pathway downstream
to p53. Expression of phosphorylation-deficient NCL mutant
causes a reduced fraction of cells in S-phase that ultimately leads to
an inhibition of cell proliferation presumably by initiating
apoptosis pathway (Figure 7). In contrast, NCL-WT expression
causes pulsatile p53 and p21 protein levels that allow cells to
survive probably by resuming the cell cycle progression.
Figure 4. NCL-6/S*A expression causes p53-dependent inhibition of cell proliferation. (A) Ctrl (no exogenous NCL) and inducible NCL
cells (WT or 6/S*A, induced for 6–8 d and 28 d) were analyzed for the DNA content by propidium iodide staining and flowcytometry. NCL-6/S*A
expressing cells have significant low % of cells in the S-phase as compared to WT expressing or Ctrl cells (**p value #0.005). (B) Reduced % of cells in
S-phase with 6/S*A expression for 10 d as assayed by Click-iT EdU flow cytometry kit (Invitrogen). Analyses were performed using FlowJo 9 software.
The data is representative of three independent experiments performed with inducible NCL cells (WT or 6/S*A, induced for 10–20 d). (C) Continuous
expression of 6/S*A (17 d) is inhibitory to cell-proliferation as analyzed by MTS assay. The data is representative of at least three independent
experiments performed with Ctrl, WT or 6/S*A (inducible NCL) cells. Each point represents the mean 6 SD of 6–8 replicates. (D) Inhibition of
proliferation by NCL-6/S*A expression requires p53. HCT116-p53 wt or null cells were transfected with NCL-WT or -6/S*A, and assayed for cell
proliferation using MTS solution. Each point represents the mean 6 SD of 6–8 replicates.
doi:10.1371/journal.pone.0109858.g004
Figure 5. NCL-WT and 6/S*A interact with endogenous NCL.
Nuclear extracts (NE) were prepared from cells grown without Dx for at
least 10 d for NCL-WT or 6/S*A expression. Ctrl represents control cells
without exogenous NCL expression. Equal amounts of NE protein from
these cells were then subjected to co-immunoprecipitation using anti-
FLAG M2 beads. Western analyses of NE and bound fractions were
analyzed by anti-NCL (to detect: -exogenous 3xFlag-tagged NCL, upper
band and –endogenous NCL, lower band), anti-Flag, anti-p53 and anti-
p21. Anti-TOPOII b blot serves as the loading control for NE. The data is
representative of three independent experiments performed with 10 d–
20 d of WT or 6/S*A expression. This data supports the hypothesis that
NCL (both WT and 6/S*A) can associate with endogenous NCL (i.e. NCL-
NCL interactions).
doi:10.1371/journal.pone.0109858.g005
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In recent years, modulation of the stress response (via activated
p53 checkpoint) by nucleolar factors has been recognized to play
an important role in tumorigenesis [56–60]. NCL, the major
nucleolar protein regulates p53-signaling at multiple levels: in
exponentially dividing cells, heightened NCL levels can trigger a
p53-checkpoint by NCL binding to Hdm2 and reducing p53
ubiquitination [8,9]. This may reflect a feedback mechanism that
serves to prevent hyperproliferation induced by abnormally high
NCL levels. During the DNA damage response, NCL can
translocate from its usual nucleolar locations to nucleoplasm
where it can modulate the translation of p53 through NCL-RPL26
or NCL-NCL oligomerization [40] and/or regulate p53 protein
Figure 6. NCL-6/S*A expression results in an increased expression of apoptotic markers downstream the p53 pathway. (A) Western
blot analyses for cells grown without Dx for the indicated period indicating inducible NCL-expression (WT or 6/S*A). Both WT and 6/S*A expression
resulted in an increase in p53 and p21 protein levels. Increased expression of BH3-only pro-apoptotic markers (BID, BIM and PUMA) were observed as
early as 1 d or 4 d of induced NCL-6/S*A expression. (B) Plots of p53, p21 and BH3-only protein levels shown in 6A. The quantification was done by
NIH Image J software. Values were first corrected for the b-actin levels and then compared to Ctrl (no exogenous NCL, no Dx day 1) cells. The graph is
representative of at least two independent experiments.
doi:10.1371/journal.pone.0109858.g006
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through direct interactions with p53 [5,7,9] or its antagonist
Hdm2 [8,9].
In this study we extend the regulation of p53 by NCL
phosphorylation demonstrating that dephosphorylation at CK2
sites leads to ‘‘nucleolar stress’’ like conditions that allow NCL to
mobilize and activate the p53 signaling pathway. In fact, both WT
and 6/S*A expression increase the p53 protein levels from day1
and we observe an increased p53 protein stability associated with
NCL-mutant expression. We frequently observe more dynamic
p53 levels with NCL-WT expression while p53 levels persist with
continuous NCL mutant expression. Remarkably, only induced
NCL-6/S*A expression (even in the presence of the endogenous
NCL) results in a dominant-negative effect on cell proliferation
that is predominantly p53-mediated. We envision that NCL-6/
S*A negates the effects of endogenous NCL through oligomeri-
zation and indeed we observe interactions between endogenous-
NCL and exogenous-NCL (WT or 6/S*A) in our co-IP assays to
support this concept. Future stoichiometric analyses between
nucleolin and its different phosphorylation forms will provide
more insights about nucleolin oligomerization and its physiological
implications. In contrast, WT cells survive and proliferate through
fluctuating p53 levels. Recently from single cell analyses, the
phenomenon of pulsed versus sustained p53 levels and different
cellular fate has provided useful insights about p53 control of gene
expression in DNA repair, apoptosis and senescence pathways
[61]. Expression of phosphorylation-deficient NCL results in
consistent p53 levels and activates pro-apoptotic proteins e.g. BID
and PUMA. These BH3-only proteins expression is known to be
transcriptionally activated upon DNA-damaging chemotherapeu-
tic agents to activate the destructive caspase cascade resulting in
cell death. Although our data strongly support that NCL mutant
requires p53-mediated signaling in restricting cell proliferation, a
p53-independent increase of PUMA and BIM cannot be
completely ruled out. It is also possible that targeting NCL
phosphorylation by CK2 could synergistically initiate a broader
range of BH3-only proteins for more efficient retardation of
proliferation.
Together, hypophosphorylated NCL with more nucleoplasmic
localization presumably causes ‘‘nucleolar stress’’ like conditions
that can trigger multiple events: NCL binds to p53-protein and
RNA directly or modulates p53 levels through interactions with
other p53-regulators (e.g. Hdm2 or RPL26); other nucleolar
factors can similarly sense this stress to regulate p53 checkpoint
[62]. Thus, increases in p53-levels in NCL-mutant expressing cells
could be the net result of these direct and indirect events.
Occasionally larger nucleoli associated with inducible NCL
expression could reflect its functional capability; more nucleolar
specific RNA cytochemistry analyses are warranted to identify a
role for NCL hypophosphorylation in these processes. Future
studies with single cell analyses will prove highly useful in
validating the functional impacts of NCL hypophosphorylation
in regulating the kinetics of the p53 signaling pathway.
It is worth mentioning that NCL is also an important RNA
binding protein that regulates gene expression through direct
NCL/RNA interactions or indirectly by recruiting other molecules
in RNA metabolism. Importantly, the N-terminus and the RNA
binding domains of NCL are positioned adjacently and hence can
influence NCL protein conformation and/or functional properties
[47]. In spite of this association, due to the highly-acidic nature of
the N-terminus and technical issues of purifying full-length NCL,
the role of NCL phosphorylation has been overlooked while
studying many of its physiological functions. These NCL
constructs and clones are therefore valuable in facilitating the
full-length NCL purification through its tag (His, Flag). Addition-
ally, these cells have an ability to express p14ARF tumor
suppressor protein that lies upstream to the p53 checkpoint
activation, more commonly during oncogenic stimulation. Using
the inducible expression of NCL in this study we reveal for the first
time how CK2-mediated NCL phosphorylation, provides neces-
sary quality control surveillance on the major cellular decision of
cell survival.
Material and Methods
Cell culture and reagents
U2OS (osteosarcoma, p53-wt, ARF-null) cells were obtained
from ATCC (American Type Cell Culture). NARF cells [41] were
kindly provided by Dr. Gordon Peters. All cell lines were grown in
DMEM containing 10% FBS and 100 units penicillin-streptomy-
cin, at 37uC with 5% CO2 atmosphere in a humidified incubator.
Plasmid transfections were performed using Effectene transfection
reagent (Qiagen). SIGMAFAST protease inhibitor cocktail tablets
(Sigma-Aldrich, St Louis, MO, USA) were used at 16 concentra-
tions as per the manufacturer’s instructions. For various
treatments, the drugs were directly added to the growth media
to a final concentration as indicated: Isopropyl b-D-1-thiogalacto-
pyranoside (IPTG, Sigma-Aldrich) at 1 mM; camptothecin (CPT,
Sigma-Aldrich; a stock concentration of 10 mM in DMSO) at
2 mM; 5, 6-Dichloro-1-b-D-ribofuranosylbenzimidazole, DRB (a
CK2 inhibitor, Sigma- Aldrich) at 40-60 mM and cycloheximide
(CHX, Sigma- Aldrich) at 40 mg/ml for indicated time periods.
For UV treatment, cultures at 90% confluency were exposed to
UV dose (50 J m22) using a UVP HL-2000 HybriLinker (with a
254 nm UV cross linker from Fisher Scientific). Before pulsing, the
medium was removed and same medium was replaced immedi-
ately after treatment. All reagents were of molecular or cell culture
Figure 7. Mechanistic model by which nucleolin phosphorylation by CK2 regulates cell proliferation. NCL-WT and phosphorylation-
deficient mutant (6/S*A) activate p53 checkpoint and increase corresponding p21 levels. However, NCL-WT expression allows cells through S-phase
progression and resumes cell cycle. On the other hand, NCL-6/S*A acts as a dominant-negative mutant that negates NCL-WT functions possibly
through oligomerization causing inhibition of cell proliferation and initiating apoptotic pathway.
doi:10.1371/journal.pone.0109858.g007
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grade and were obtained from Fisher Scientific unless otherwise
mentioned.
Antibodies
The primary antibodies used for Western blotting were as
follows: GFP, rabbit polyclonal (Molecular Probes, Invitrogen
Corp. Carlsbad, CA, USA); FLAG, M2-monoclonal or rabbit
polyclonal and b-actin, mouse monoclonal (all from Sigma-
Aldrich, St Louis, MO, USA); p14ARF (14P02, rabbit polyclonal,
Thermo Fisher Scientific Biosciences); NCL, mouse monoclonal
MS-3 and rabbit polyclonal H250, NPM (B23, 0412), mouse
monoclonal, p53 mouse monoclonal DO-1, PCNA, rabbit
polyclonal and TOPO II b, mouse monoclonal (all from Santa
Cruz Biotechnology, Santa Cruz, CA, USA). Pro-apoptotic Bcl2
family antibody kit and anti-p21, mouse monoclonal were
purchased from Cell Signaling technology. The secondary
antibodies used were anti-mouse and anti-rabbit HRP-conjugated
antibodies (GE Healthcare Bio-Sciences Corp. Piscataway, NJ,
USA). Various reagents for protein purification and biochemical
assays were purchased commercially including Ni+2-NTA agarose
beads (Qiagen, Valencia, CA, USA) and FLAG M2 beads (Sigma-
Aldrich, St Louis, MO, USA).
NCL mutagenesis and retroviral infection
The expression constructs for human nucleolin (NCL, NCBI:
NP_005372.2 or UniProt: P19338); full-length (FL, aa 1-710)
containing an N-terminal GFP-tag was described previously [7,8].
Earlier we have generated NCL phospho-mutants with three
putative CK2 sites at positions S34, S184, and S206 converted to
non-phosphorylatable alanine [3/S*A, earlier designated as NCL-
TM, triple mutant [7]]. Subsequently, we mutated three
additional CK2 phosphorylation sites to further lower phosphor-
ylation by CK2 [24,25,63] and generated a novel reagent 6/S*A
(six serine mutated to alanine: S28A, S34A, S145A, S153A,
S184A, S206A). Sequential site-directed mutagenesis for NCL
phospho-mutants was done using the QuikChange site-directed











Constructs with different tags (e.g. His, FLAG and GFP) were
created for NCL (-WT or 6/S*A). PCR reactions (for WT and 6/
S*A constructs) were performed using 3xFlag-tagged NCL as a
template and generated full-length NCL coding sequence with the
primers that contain Not I and BamH I sites in the forward and
reverse primers respectively. PCR products were subcloned into
the Not I/BamH I sites on the pRetro-Off retroviral vector
(Clontech). Production of retroviruses containing the NCL (WT or
6/S*A) expression cassettes were performed in Phoenix cells
(Retroviral Helper dependent protocol, https://www.stanford.
edu/group/nolan/protocols/pro_helper_dep.html). Subsequent-
ly, NARF6 cells were infected with retroviral constructs (NCL-
WT or 6/S*A). Stable clones that allow inducible expression of
either 3xFlag tagged NCL-WT or -6/S*A driven by a Tet-Off
inducible promoter were isolated and expanded as described
elsewhere [64]. Multiple clones that can turn on NCL expression
by removal of doxycycline (Dx, semi-synthetic tetracycline) from
the culture medium were selected. Addition of doxycycline in
contrast, shuts off exogenous NCL expression ,90% in these
selected clones. These NCL-clones were grown without doxycy-
cline in the medium for the indicated time (hours or days) for
NCL-expression and used in subsequent biological and biochem-
ical assays as described. In each selective assay, analyses of
multiple days of NCL-induction were included to obtain a
representative outcome and possible insights into dose-dependent
response.
Purification of NCL phospho-variants
His-tagged NCL proteins were purified on Ni2+-NTA Agarose
beads (Qiagen), using the manufacturer’s protocol. Briefly, U2OS
cells were transfected with constructs expressing His-tagged NCL
(WT or 6/S*A). At 48 h post-transfection, cells were lysed in
buffer containing 50 mM NaPO4 pH 7.4, 1% (v/v) NP-40, 0.05%
(v/v) Tween 20, 0.5 M NaCl, 20% (v/v) glycerol, 20 mM
imidazole, 0.5 mM phenylmethylsulfonyl fluoride (PMSF),
2 mM sodium vanadate (Na3VO4), 50 mM NaF, 1 mM dithio-
threitol (DTT) and benzonase. His-tagged proteins were purified
using Ni2+-NTA agarose beads by incubating for 2 h at 4uC on a
shaker. Beads were washed 5 times with wash buffer [50 mM
NaPO4 pH 7.4, 200 mM NaCl, 20% (v/v) glycerol, 20 mM
imidazole, 0.5 mM PMSF, 2 mM Na3VO4, 50 mM NaF, and
1 mM DTT]. Proteins were then eluted with elution buffer
(50 mM NaPO4, pH 7.4, 300 mM imidazole, and 20% glycerol).
Afterwards, the eluate was dialyzed overnight at 4uC against
phosphate-buffered saline (PBS) and 20% glycerol in the presence
of protease inhibitors. Purified proteins in the eluate were assayed
for purity by SDS-polyacrylamide gel electrophoresis (PAGE) and
Coomassie blue staining.
Phosphorylation assay
To assess NCL phosphorylation, the NCL variants were
purified as described above and were analyzed by SDS-PAGE,
using two 6% polyacrylamide gels. One gel was fixed in a solution
containing 50% methanol and 10% acetic acid, and first stained
using Pro-Q Diamond phosphoprotein gel stain (Molecular
Probes) in accordance with the manufacturer’s instructions. The
Pro-Q Diamond staining specific for phosphorylated protein was
visualized on a Typhoon Trio scanner (GE Healthcare) using
excitation at 532 nm florescence and 555 BP 20 filter to record
emission. The same gel was subsequently stained with SYPRO
Ruby (Molecular Probes) for total protein analysis and emission
recorded using 610 BP 30 filter. The second parallel gel was
transferred onto a nitrocellulose membrane for Western analyses
and was probed for anti-NCL. Intensities of bands corresponding
to phosphorylated nucleolin (from Pro-Q staining) and total
nucleolin (from SYPRO staining) were determined by Image J
analysis. Relative nucleolin phosphorylation ratio was then
calculated for the Pro-Q signals of NCL-6/S*A to that of NCL-
WT, after normalizing for the amount of total nucleolin.
NCL phosphorylation in vivo
U2OS cells were transfected with GFP-tagged NCL-WT and
labeled metabolically with 32PO4 for 90 minutes. CK2 inhibitor,
DRB was used at 40 mM for 24 h as indicated. We performed
immunoprecipitation (IP) assay to pull-down tagged-NCL. IP
fractions were subjected to SDS-PAGE and the relative amount of
total 32PO4 incorporation in NCL-WT was assayed by autoradi-
ography. IP fractions were also detected using anti-NCL
antibodies on a parallel Western blot to confirm equal amount
of immunoprecipitates in each sample. Simultaneously, sub-
nuclear localization of GFP-tagged NCL-WT in the presence or
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absence of DRB was recorded using an epifluorescence micro-
scope (Olympus IX71).
Immunofluorescence staining
Immunofluorescence technique was employed essentially as
described earlier [8]. Briefly, cells were first split onto coverslips,
either transfected or induced for NCL expression (15–29 d of Dx
removal). Post-36h of transfection or indicated time point
following induction cells were either mock- or CPT-treated. For
treatment, cells were incubated with camptothecin (CPT, 2 mM
for 2 h) or exposed to UV dose (50 J m22) and incubated post-UV
for 25 min. Cells were then washed with PBS and fixed with 4%
(w/v) paraformaldehyde. Next, cells were permeabilized with
0.5% (v/v) Triton X-100 in PBS for 5 min at RT. After washing
twice with PBS, coverslips were then either directly viewed using
FITC filter (for GFP-NCL expression) or incubated with rabbit
anti-Flag primary antibodies (for 3xFlag-NCL) followed by Alexa-
594 labeled anti-mouse secondary antibodies (Molecular Probes
Inc.). Image acquisition was performed using Olympus IX71
inverted epifluorescence and Olympus FV10i confocal scope
(Tokyo, Japan).
Semi-quantitation of nucleolar vs. nucleoplasmic staining was
performed using Metamorph advanced analyses program (Molec-
ular Devices, Sunnyvale, CA). Briefly, each nucleus following
nucleolin immunostaining was photomicrographed at the constant
light level with a 406objective. Each photomicrograph was taken
consecutively using Texas Red and DAPI filter sets (Chroma,
Bellow Falls, VT). For each image, using the threshold above the
background, total number of nuclei were selected and then
quantified using MetaMorph’s Integrated Morphometry Analysis
(IMA) feature. Using DAPI mask, first the total number of nuclei
were identified and average integrated intensities of each nucleus
was measured using Texas Red filter. Similarly, by copying few
nuclei regions (outlines) into the non-cell areas of the image,
background intensities were measured. The average of back-
ground intensities were subtracted from the total nuclear measured
intensities. Next, by changing the threshold value integrated
intensities of all the nucleoli were measured similarly in the red
channel. Nucleoplasmic staining intensity was obtained by
subtracting the total nucleolar staining from the nuclear staining
and % staining for each sub-nuclear location (nucleolar and
nucleoplasmic) were calculated. X/Y location parameters were
used to identify each nucleus and its corresponding nucleoli. The
size and area filters were employed to minimize intrinsic variability
in size of the nuclei. To quantitate the sub-nuclear distribution of
NCL localization, we examined a total of ,80–100 nuclei with
differential levels of NCL expression (low, medium and high) for
both WT and 6/S*A. Sub-nuclear distribution of NCL in cells
(n = 30 for each WT and 6/S*A) with moderate level of NCL
expression as determined by the integrated morphometric analyses
were used to achieve statistical analyses.
FRAP analysis
U2OS cells were grown and transfected with the appropriate
GFP-tagged expression constructs (NCL-WT or 6/S*A) in 35-mm
uncoated glass bottom cell culture dishes (MatTek). Twenty-four
hours post-transfection, cells were either untreated or treated with
CPT as described above. Under our conditions, U2OS cells
contain an average of 4 to 8 nucleoli per cell. Live cell images were
obtained with a Zeiss LSM510 Meta laser scanning confocal
microscope with a Plan-Apochromat 636objective (1.4 NA) and a
30-mW Argon laser set at 50% of total output. Prior to
photobleaching, five images were taken of the nucleus containing
the nucleolar region of interest (ROI). One nucleolus per cell was
therefore chosen as an ROI and bleached using the 488 nm laser
line. After photobleaching of the ROI, images were then acquired
every 5 seconds for at least 60 seconds, when fluorescence had
recovered to maximal intensity for at least 15 sec. At least 10
datasets were analyzed for each result. Fluorescence intensity was
measured using Zeiss image-processing software. The average
intensity in the ROI before bleaching, immediately after bleaching
and post bleaching was measured. Fluorescence intensity of
the nucleus was also measured. Background fluorescence was
measured in a field outside the cell and subtracted from
the nucleolar and nuclear fluorescence values. The relative




Where ROI (t) is the average fluorescence intensity of the
photobleached region at various time points after photobleaching,
Nucleus (t) is the average fluorescence intensity of the entire
nucleus at the corresponding time point, ROI (t0) is the average
fluorescence intensity of the photobleached region before photo-
bleaching (time zero), and Nucleus (t0) is the average fluorescence
intensity of the entire nucleus before photobleaching. Non-linear
curve fitting of the recovery data was carried out using ORIGIN
(Microcal Software). The fluorescence recovery (F) was plotted
against time (t) and t1/2 was calculated using the equation:
F (t)~az½(b{a)|t=(tzc) where ‘a’ is the intensity value
immediately after bleaching, ‘b’ is the maximum intensity value
and ‘c’ is t1/2.
Nucleolin replacement strategy and silencing
For replacement of endogenous NCL, NCL-expressing clones
were first grown for the indicated period in medium lacking
doxycycline to allow ectopic NCL expression. The endogenous
NCL was then downmodulated using an siRNA (purchased from
Dharmacon, Inc, Thermo Fisher Scientific Biosciences) molecule
that targets the 39UTR of NCL gene using siNCL-A4 Target
sequence: GAGUUGAGUGAUAGAGCUAUU. In contrast,
siNCL-A2 Target sequence GCAAAGAAGGUGGUCGUUU
targets coding region of NCL gene and hence affects both
endogenous as well as exogenous NCL (i.e. the Flag-tagged NCL).
Silencing was achieved using RNAiMax (Invitrogen) as per the
manufacturer’s instructions. Two consecutive siRNA treatments
were performed to achieve higher level of NCL downregulation.
Cells were tested 72 h post-transfection (,36–40 h post 2nd
siRNA treatment). siGENOME non-targeting siRNA2 (Dharma-
con, Inc, Thermo Fisher Scientific Biosciences) was used as control
siRNA (Ctrlsi).
Nuclear extract preparation and co-immunoprecipitation
assay
NEs were prepared from harvested cells using standard
protocols. Briefly, cells were lysed by douncing in 4 ml of
hypotonic buffer [10 mM Tris pH 8.0, 1.5 mM MgCl2, 10 mM
KCl, 16 protease inhibitor cocktail and 0.5 mM PMSF]. Lysates
were centrifuged for 10 min at 6000 g, and pellets were
resuspended in nuclear extraction buffer (50 mM Tris pH 8.0,
150 mM NaCl, 1.0 mM EDTA, 1% Triton X-100, 1x protease
inhibitor cocktail and 0.5 mM PMSF). Preparations were rocked
for 30 min at 4uC and centrifuged for 15 min at 10 000 g.
Supernatants were quick frozen and stored at 280uC. 10% of NE
was saved and ,100–200 mg of total protein from NE were
immunoprecipitated using EZview red anti-FLAG M2 Affinity Gel
(Sigma) to pull-down Flag-tagged NCL following manufacturers’
recommendations. Protein estimation is performed by Coomassie
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Plus (Bradford) Protein Assay (Thermo Fisher Scientific Biosci-
ences).
Western blot assay
Cells were directly lysed in 26SDS dye and separated by SDS-
PAGE. Proteins were then immobilized onto nitrocellulose
membranes (0.2 mm pore size). After blocking in non-fat dry milk
(0.5%, w/v) for 1 h at RT, the membrane was incubated with
primary antibodies at 4uC overnight, HRP-conjugated anti-mouse
IgG or anti-rabbit IgG was used as secondary antibody. The
membranes were visualized by ECL-plus reagent (Perkin-Elmer,
Wellesley, MA, USA), scanned and analyzed using ImageQuant
LAS 4000 biomolecular imager (GE Healthcare Bio-Sciences AB,
Sweden). NIH Image J software was used to quantitate band
intensities of Western blots. Values were first corrected for the
corresponding loading control and the normalized value of a
particular marker as against the experimental control is then
presented below each blot, as indicated. Lighter intensity blots
were used in analyses by Image J. Darker exposure blots are also
provided, when required. Multiple blots were used to quantitate
various markers and different samples. Spliced out and combined
lanes are clearly indicated with the vertical lines in the figures.
Protein half-life assay
Cells were continuously grown in DMEM medium without Dx
to induce expression of 3xFlag-tagged NCL-WT or -6/S*A for
indicated period. Protein synthesis was inhibited by incubating
cells with 40 mg/ml cycloheximide (CHX). Cells were lysed with
26SDS-PAGE dye at various times post-CHX incubation as
indicated. Lysates were then analyzed by Western blotting for p53,
FLAG (for NCL expression) and the b-actin loading control.
Flow Cytometry Analyses
Cells were trypsinized by 0.25% Trypsin-EDTA solution and
then washed with PBS twice. Cells were fixed by drop-wise
addition into ice-cold 70% ethanol and incubated on ice for
30 min. Cells were then stained with 0.5 ml of a solution
containing PBS, 100 mg/ml propidium iodide (Sigma), 0.1% (v/
v) Triton X-100, and 200 mg/ml RNase A, overnight at 4uC. Cells
were analyzed next day by a BD Accuri C6 flow cytometer (BD
Biosciences). For detection of cells specifically in the S-phase,
Click-iT EdU Alexa Fluor 488 flow cytometry kit (Invitrogen) was
used as per manufacturer’s instructions. We used Becton-
Dickinson FACSort to measure the fraction of cells in S-phase
using CellQuest Pro software (BD Biosciences). Flow data were
then analyzed using FlowJo 9 and positive EdU signal is indicated
as the S-phase cell population.
Cell proliferation assays
MTS [3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphe-
nyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] assay was used
to determine cell proliferation rate. Cells were split at 5000/well
into 96-well plates, and harvested at 24 h, 48 h, 72 h, and 96 h.
Following harvesting, CellTiter 96 AQueous One Solution Cell
Proliferation Assay (MTS) solution (Promega) was added at
20 ml/well and incubated 4 h at 37uC. OD values were measured
at 490 nm by BioTek plate reader.
Supporting Information
Figure S1 Sub-nuclear distribution of NCL (WT and 6/
S*A). Inducible NCL cells grown without doxycycline for 15–29d
were used to detect NCL by immunofluorescence using anti-Flag
antibodies. Image acquisition was done with constant parameters
between the samples. Integrated Morphometry Analysis (IMA)
was performed for ,80–100 nuclei as described. Upper panel is
representative image at moderate level of NCL expression. The
graph represents sub-nuclear distribution of moderately expressed
NCL (WT or 6/S*A) in cells (n = ,30 for each). As indicated, we
observe that a significantly larger fraction of nuclear 6/S*A
(60.064.0%, **p,0.005) was localized in the nucleoplasm as
compared to that of WT (which is only at 35.568.5% of the total).
Scale bar represents 10 mm.
(TIF)
Figure S2 Sub-nuclear mobilization of NCL (WT and 6/
S*A). U2OS cells were transfected with GFP-NCL (WT and 6/
S*A). Post 24 h of transfection, cells were either untreated or
treated with CPT and FRAP was performed as described. FRAP
analyses suggests GFP-6/S*A mutant is slightly more mobile
within the nucleoli with shorter recovery time seen after
photobleaching. Although genotoxic stress (treatment with camp-
tothecin, CPT, 2 mM for 2 h) caused greater mobility of both WT
and the 6/S*A mutant, the mutant consistently showed higher
mobility compared to WT under these conditions. *Statistically
different from NCL-WT, p,0.05.
(TIF)
Figure S3 In vivo NCL phosphorylation. 32PO4 metabolic
labeling followed by NCL-IP (immunoprecipitation) resulted in
reduced phosphorylation in the presence of CK2 inhibitor DRB.
Anti-NCL represents Western blot. Corresponding sub-nuclear
localization with GFP-NCL transfection in U2OS cells suggests
that NCL mobilization to nucleoplasm is concurrent with
hypophosphorylation observed in the presence of CK2 inhibitor.
(TIF)
Figure S4 NARF6-NCL clones express p14ARF upon
IPTG induction and stabilize p53. NARF6-NCL clones
were grown without doxycycline for 15 d and 1 mM IPTG was
added for another 22 h. Lysates were obtained from inducible
NCL clones (C1 and C2) or Ctrl (vector expressing) clone. Western
blots representing 3xFlag-NCL or p14ARF expression upon
activation of Tet-off or IPTG-induced promoter, respectively.
Both NCL and p14ARF expression increases p53 and its
downstream target p21 protein levels. PCNA was used as loading
control while NPM (nucleophosmin) was used as nucleolar protein
control. ‘+’ indicates with, ‘-’ indicates without. Spliced out and
recombined lanes are denoted by a vertical line.
(TIF)
Figure S5 Half-life analyses of p53 and endogenous NCL
upon p14ARF expression. NARF6 cells were induced for
p14ARF expression by 1 mM IPTG treatment for 22 h. The half-
life of p53 protein upon robust p14ARF expression is beyond 2 h.
Endogenous NCL half-life remains overall unaltered (,6 h or
more) although a transient increase (lane 3 vs. lane 2) upon
p14ARF expression is consistently observed. Spliced out and
recombined lanes are denoted by a vertical line.
(TIF)
Figure S6 NARF6-NCL clones as NCL-replacement tool.
Inducible NCL cells grown without doxycycline for 10 d were
used to selectively downregulate endogenous NCL. Following two
subsequent siRNA transfection and post 36 h of second siRNA
treatment, lysates were prepared. Western blot analyses of both
endogenous (lower band) and induced NCL (upper band)
expression were performed by anti-NCL antibodies to achieve
reliable normalized levels. Normalized values against actin using
NIH Image J software is represented below each blot. As
indicated, up to 70% reduction of endogenous NCL protein was
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achieved. The expression of induced NCL (i.e. the Flag-tagged
NCL) remained unchanged (as indicated by anti-NCL as well as
anti-Flag blots).
(TIF)
Figure S7 Half-life analyses of p53 at earlier time points
upon inducible NCL (WT or 6/S*A) expression. Upper
panel, the graph shows evaluation of p53-stability for shorter time
period following cycloheximide blocking upon NCL (WT or 6/
S*A) expression in the absence of doxycycline (16 d–22 d). As
indicated, the p53 half-life is lower in cells expressing WT
(,30–40’) as compared to mutant (,1 h), while control cells have
normal half-life of ,15–20’. Lower panel, assuming the decrease
in p53 protein levels is a pseudo-first order kinetic process, the data
presented in Figure 3B were plotted on a log scale to indicate a
higher p53 protein half-life in cells with mutant-NCL expression.
(TIF)
Figure S8 NCL expressing clones have similar cell
properties. Upper panel, the three cell lines (Ctrl, or expressing
inducible NCL-WT or NCL-6/S*A) have comparable standard
curve as analyzed using MTS assay. Lower panel, in the absence of
induced NCL expression (i.e. in the presence of doxycycline), all
Ctrl, NCL-WT or NCL-6/S*A cells have similar proliferation
rates.
(TIF)
Figure S9 Induced NCL-6/S*A expression (10-24 d)
activates p53 checkpoint and apoptosis pathway. Upper
panel, Inducible NCL (WT or 6/S*A) cells were grown without
Dx for 10–24 days. Western blots indicating inducible NCL-
expression (WT or 6/S*A) by anti-Flag antibodies. Both WT and
6/S*A expression resulted in an increase in p53 and p21 protein
levels. However, higher expression of BH3-only pro-apoptotic
markers (BID and PUMA) were primarily associated with NCL-6/
S*A expression. The quantification was done by NIH Image J
software. Values were first corrected for the b-actin levels, then
compared to Ctrl cells and indicated below each blot. Lower panel,
Scatter plots of p53, p21 and BH3-only protein levels shown in
upper panel. The data is representative of at least two independent
experiments.
(TIF)
Figure S10 Cumulative expression pattern of markers
in the p53 and apoptotic signaling upon NCL expression.
A cumulative scatter plot for all the combined data (with as little as
24 h to as long as 28 days of induced NCL expression) clearly
reveals increased levels of p53, BID and PUMA with NCL-6/S*A
expression as compared to WT or Ctrl cells These data are derived
from multiple Westerns and presented as combined plots for the
p53, p21 and BH3-only pro-apoptotic markers (BID, BIM and
PUMA) protein levels. The quantification was done by NIH
Image J software. Values were first corrected for the b-actin levels
and then compared to Ctrl (no exogenous NCL, no Dx day 1 or 7)
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